Outcomes of granulocyte colony-stimulating factor use in pediatric kidney transplant recipients: A Pediatric Nephrology Research Consortium study
dc.contributor.author | Engen, Rachel M. | |
dc.contributor.author | Weng, Patricia L. | |
dc.contributor.author | Shih, Weiwen | |
dc.contributor.author | Patel, Hiren P. | |
dc.contributor.author | Richardson, Kelsey | |
dc.contributor.author | Dowdrick, Shauna L. | |
dc.contributor.author | Ashoor, Isa F. | |
dc.contributor.author | Misurac, Jason | |
dc.contributor.author | Traum, Avram Z. | |
dc.contributor.author | Semanik, Michael G. | |
dc.contributor.author | Jain, Namarata G. | |
dc.contributor.author | Mansuri, Asifhusen | |
dc.contributor.author | Sreedharan, Rajasree | |
dc.date.accessioned | 2022-05-06T17:28:59Z | |
dc.date.available | 2023-06-06 13:28:57 | en |
dc.date.available | 2022-05-06T17:28:59Z | |
dc.date.issued | 2022-05 | |
dc.identifier.citation | Engen, Rachel M.; Weng, Patricia L.; Shih, Weiwen; Patel, Hiren P.; Richardson, Kelsey; Dowdrick, Shauna L.; Ashoor, Isa F.; Misurac, Jason; Traum, Avram Z.; Semanik, Michael G.; Jain, Namarata G.; Mansuri, Asifhusen; Sreedharan, Rajasree (2022). "Outcomes of granulocyte colony-stimulating factor use in pediatric kidney transplant recipients: A Pediatric Nephrology Research Consortium study." Pediatric Transplantation (3): n/a-n/a. | |
dc.identifier.issn | 1397-3142 | |
dc.identifier.issn | 1399-3046 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/172325 | |
dc.description.abstract | BackgroundNeutropenia is common in the first year after pediatric kidney transplant and is associated with an increased risk of infection, allograft loss, and death. Granulocyte colony-stimulating factor (G-CSF) increases neutrophil production, but its use in pediatric solid organ transplant recipients remains largely undescribed.MethodsWe performed a multicenter retrospective cohort study of children with neutropenia within the first 180 days after kidney transplant. Multivariable linear regression and Poisson regression were used to assess duration of neutropenia and incidence of hospitalization, infection, and rejection.ResultsOf 341 neutropenic patients, 83 received G-CSF during their first episode of neutropenia. Median dose of G-CSF was 5 mcg/kg for 3 (IQR 2–7) doses. G-CSF use was associated with transplant center, induction immunosuppression, steroid-free maintenance immunosuppression, hospitalization, and decreases in mycophenolate mofetil, valganciclovir, and trimethoprim–sulfamethoxazole dosing. Absolute neutrophil count nadir was also significantly lower among those treated with G-CSF. G-CSF use was not associated with a shorter duration of neutropenia (p = .313) and was associated with a higher rate of neutropenia relapse (p = .002) in adjusted analysis. G-CSF use was associated with a decreased risk of hospitalization (aIRR 0.25 (95%CI 0.12–0.53) p < .001) but there was no association with incidence of bacterial infection or rejection within 90 days of neutropenic episode.ConclusionG-CSF use for neutropenia in pediatric kidney transplant recipients did not shorten the overall duration of neutropenia but was associated with lower risk of hospitalization. Prospective studies are needed to determine which patients may benefit from G-CSF treatment. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.subject.other | G-CSF | |
dc.subject.other | adverse effect | |
dc.subject.other | neutropenia | |
dc.subject.other | pediatric | |
dc.subject.other | pediatric kidney transplant | |
dc.title | Outcomes of granulocyte colony-stimulating factor use in pediatric kidney transplant recipients: A Pediatric Nephrology Research Consortium study | |
dc.type | Article | |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Pediatrics | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/172325/1/petr14202_am.pdf | |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/172325/2/petr14202.pdf | |
dc.identifier.doi | 10.1111/petr.14202 | |
dc.identifier.source | Pediatric Transplantation | |
dc.identifier.citedreference | Khalil MAM, Khalil MAU, Khan TFT, Tan J. Drug-induced hematological cytopenia in kidney transplantation and the challenges it poses for kidney transplant physicians. J Transplant. 2018; 2018: 1 - 22. doi: 10.1155/2018/9429265 | |
dc.identifier.citedreference | Turgeon N, Hovingh GK, Fishman JA, et al. Safety and efficacy of granulocyte colony-stimulating factor in kidney and liver transplant recipients. Transpl Infect Dis. 2000; 2 ( 1 ): 15 - 21. Accessed May 1, 2018. http://www.ncbi.nlm.nih.gov/pubmed/11429005 | |
dc.identifier.citedreference | Mehta HM, Malandra M, Corey SJ. G-CSF and GM-CSF in neutropenia. J Immunol. 2015; 195 ( 4 ): 1341 - 1349. doi: 10.4049/jimmunol.1500861 | |
dc.identifier.citedreference | Hurst FP, Belur P, Nee R, et al. Poor outcomes associated with neutropenia after kidney transplantation: analysis of United States renal data system. Transplantation. 2011; 92 ( 1 ): 36 - 40. doi: 10.1097/TP.0b013e31821c1e70 | |
dc.identifier.citedreference | Zafrani L, Truffaut L, Kreis H, et al. Incidence, risk factors and clinical consequences of neutropenia following kidney transplantation: a retrospective study. Am J Transplant. 2009; 9 ( 8 ): 1816 - 1825. doi: 10.1111/j.1600-6143.2009.02699.x | |
dc.identifier.citedreference | Becker-Cohen R, Ben-Shalom E, Rinat C, Feinstein S, Geylis M, Frishberg Y. Severe neutropenia in children after renal transplantation: incidence, course, and treatment with granulocyte colony-stimulating factor. Pediatr Nephrol. 2015; 30 ( 11 ): 2029 - 2036. doi: 10.1007/s00467-015-3113-7 | |
dc.identifier.citedreference | Winston DJ, Foster PF, Somberg KA, et al. Randomized, placebo-controlled, double-blind, multicenter trial of efficacy and safety of granulocyte colony-stimulating factor in liver transplant recipients. Transplantation. 1999; 68 ( 9 ): 1298 - 1304. Accessed May 1, 2018. http://www.ncbi.nlm.nih.gov/pubmed/10573067 | |
dc.identifier.citedreference | Larson R Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation - UpToDate. UpToDate. Accessed March 31, 2021. | |
dc.identifier.citedreference | Schmaldienst S, Bekesi G, Deicher R, Franz M, Hörl WH, Pohanka E. Recombinant human granulocyte colony-stimulating factor after kidney transplantation: a retrospective analysis to evaluate the benefit or risk of immunostimulation. Transplantation. 2000; 69 ( 4 ): 527 - 531. Accessed May 1, 2018. http://www.ncbi.nlm.nih.gov/pubmed/10708106 | |
dc.identifier.citedreference | Hamel S, Kuo V, Sawinski D, et al. Single-center, real-world experience with granulocyte colony-stimulating factor for management of leukopenia following kidney transplantation. Clin Transplant. 2019; 33 ( 6 ): e13541. doi: 10.1111/ctr.13541 | |
dc.identifier.citedreference | Vrtovec B, Haddad F, Pham M, et al. Granulocyte colony-stimulating factor therapy is associated with a reduced incidence of acute rejection episodes or allograft vasculopathy in heart transplant recipients. Transplant Proc. 2013; 45 ( 6 ): 2406 - 2409. doi: 10.1016/j.transproceed.2013.01.106 | |
dc.identifier.citedreference | Peddi VR, Hariharan S, Schroeder TJ, First MR. Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients. Clin Transplant. 1996; 10 ( 1 Pt 1 ): 20 - 23. Accessed May 1, 2018. http://www.ncbi.nlm.nih.gov/pubmed/8652892 | |
dc.identifier.citedreference | Jha A, Ghoz H, James N. Severe agranulocytosis following simultaneous administration of chlorpromazine and trimethoprim-sulfamethoxazole in a patient with sepsis. A possible toxic combination. Case Rep Med. 2016; 2016: 1 - 3. doi: 10.1155/2016/5653497 | |
dc.identifier.citedreference | Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009; 20 ( 3 ): 629 - 637. doi: 10.1681/ASN.2008030287 | |
dc.identifier.citedreference | North American Pediatric Renal Trials and Collaborative Studies. NAPRTCS 2014 Annual Transplant Report. Accessed March 31, 2021. https://naprtcs.org/system/files/2014_Annual_Transplant_Report.pdf Published 2014 | |
dc.identifier.citedreference | Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med. 1997; 336 ( 25 ): 1776 - 1780. doi: 10.1056/nejm199706193362502 | |
dc.working.doi | NO | en |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.